ABBOTT LABORATORIES vs Merck & Co., Inc., two Drug Manufacturers stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where ABT and MRK diverge most: on ev/ebitda, ABT reads 23.1 and MRK reads 629.4; on revenue growth, ABT reads +6.6% and MRK reads +2.9%. The rest of the comparable metrics sit closer together. On valuation, today's ABT price has a different growth bar priced in than MRK (+13.7% implied for ABT vs +11.4% for MRK); the higher figure is the steeper assumption to clear, not a better or worse stock. What ABT's price implies is a bet that sits within the historical range (whole-company basis). The bull and bear cases for each are in their full reports below.
| Metric | ABT | MRK |
|---|---|---|
| Price | $105.72 | $130.21 |
| Market cap | $184.7B | $321.9B |
| Sector | Drug Manufacturers | Drug Manufacturers |
| Stage | Mature | Mature |
| Implied growth (priced in) | +13.7% | +11.4% |
| P/E | 29.6 | 36.7 |
| P/B | 3.50 | 7.01 |
| P/S | 4.09 | 4.89 |
| EV/EBITDA | 23.1 | 629.4 |
| Revenue growth | +6.6% | +2.9% |
| Operating margin | 12.1% | — |
| Net margin | 13.9% | 13.6% |
| Return on equity | 11.9% | 19.4% |
| Return on assets | 5.7% | 6.9% |
| Return on invested capital | 6.6% | — |
| FCF yield | 4.0% | 4.4% |
| Dividend yield | 2.3% | 2.5% |
| Debt / equity | 0.65 | 1.07 |
| Current ratio | 1.39 | 1.30 |
| Altman Z (solvency) | 7.16 | 7.31 |
| Piotroski F (quality) | 6 / 9 | 6 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.